Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05317416 · ClinicalTrials.gov registry record · Phase 3

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

A Phase 3 study of Multiple Myeloma, sponsored by Pfizer.

Active
Registry status
Phase 3
Development phase
811
Enrollment target
20
Study locations

NCT05317416: Active Phase 3 study of Multiple Myeloma, sponsored by Pfizer.

NCT05317416 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 811 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05317416, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
811 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years

Primary Outcome

Progression Free Survival assessed by Blinded Independent Central review per IMWG response criteria

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Lenalidomide
  • DRUG Elranatamab

Study Locations (20)

California

  • Ronald Reagan UCLA Medical Center - Los Angeles
  • UCLA Department of Medicine - Hematology/Oncology - Los Angeles
  • UCLA Hematology/Oncology - Los Angeles
  • UCLA Hematology/Oncology - Santa Monica - Los Angeles
  • Santa Monica UCLA Medical Center & Orthopaedic Hospital - Santa Monica

Arizona

  • Banner Gateway Medical Center - Gilbert
  • Banner Gateway Medical Pavilion - Gilbert
  • Banner MD Anderson Cancer Center - Gilbert

New York

  • WMCHealth Advanced Physician Services - Hawthorne
  • Westchester Medical Center - Valhalla

Ohio

  • Cleveland Clinic - Cleveland
  • OhioHealth Arthur G.H. Bing, MD, Cancer Center - Columbus

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Florida

  • Miami Cancer Institute at Baptist Health, Inc. - Miami

Georgia

  • Winship Cancer Institute, Emory University - Atlanta

Illinois

  • Loyola University Chicago - Maywood

Trial Details

FieldValue
Enrollment Target 811 participants
Start Date 2022-03-25
Est. Completion 2029-10-31
Phase Phase 3
Pfizer

1,845 total trials

What the registry record for NCT05317416 still lists

NCT05317416 is an interventional study that assigns participants to a tested intervention. The registered 811 participants enrollment target is mid-sized for trials with a published cap, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (49% higher).

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Lenalidomide is the first listed.

NCT05317416 names 20 study sites across 12 states, led by California, Arizona, New York.

Frequently Asked Questions

What is clinical trial NCT05317416 about?

NCT05317416 is a clinical study titled "Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant". The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants...

What is the current status of trial NCT05317416?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 811 participants. The study started on 2022-03-25. Estimated completion is 2029-10-31.

What conditions does trial NCT05317416 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT05317416?

The interventions under investigation include: Lenalidomide (DRUG), Elranatamab (DRUG).

Who is sponsoring clinical trial NCT05317416?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05317416 being conducted?

This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05317416's enrollment target sits among peer trials

811 27th of 438 higher than 412 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05519085 · 810 participants · Phase 3

    A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

  • NCT06529094 · 808 participants · NA

    Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic

  • NCT07218029 · 815 participants · Phase 3

    A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

  • NCT04613596 · 806 participants · Phase 2

    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05317416, the US trial registry maintained by the National Library of Medicine. NCT05317416 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.